Caribou Biosciences, Inc. (CRBU) – What Are Analysts Thinking About This Stock?

Caribou Biosciences, Inc. (NASDAQ:CRBU) has been given an average recommendation of “Hold” by the seven analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $4.50.

A number of equities analysts have recently commented on the company. Wall Street Zen downgraded Caribou Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Leerink Partners cut shares of Caribou Biosciences from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $4.00 to $1.00 in a report on Wednesday, October 7th. Bank of America decreased their price target on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Royal Bank Of Canada downgraded shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 price objective on the stock. in a research report on Wednesday, October 7th. Finally, Brookline Capital Markets lowered shares of Caribou Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 7th.

Hedge Funds Weigh In On Caribou Biosciences

Large investors have recently bought and sold shares of the business. CTC Alternative Strategies Ltd. acquired a new stake in Caribou Biosciences in the first quarter valued at $29,000. Next Capital Management LLC acquired a new position in shares of Caribou Biosciences during the 2nd quarter worth about $35,000. The Manufacturers Life Insurance Company acquired a new position in shares of Caribou Biosciences during the 2nd quarter worth about $41,000. Spark Investment Management LLC purchased a new position in shares of Caribou Biosciences in the 2nd quarter valued at about $42,000. Finally, Sei Investments Co. purchased a new position in shares of Caribou Biosciences in the 1st quarter valued at about $59,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

CRBU opened at $0.38 on Friday. The business has a fifty day moving average price of $0.86 and a 200 day moving average price of $1.58. Caribou Biosciences has a 12 month low of $0.36 and a 12 month high of $2.49. The stock has a market capitalization of $41.08 million, a price-to-earnings ratio of -0.37 and a beta of 2.50.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $1.60 million. Caribou Biosciences had a negative return on equity of 102.74% and a negative net margin of 1,085.00%. On average, research analysts anticipate that Caribou Biosciences will post -0.94 earnings per share for the current year.

About Caribou Biosciences

Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses CRISPR gene-editing technology to engineer allogeneic, or “off-the-shelf,” immune-cell therapies designed to target cancer cells while reducing limitations associated with individualized cell treatments. Caribou’s research platform is based on CRISPR hybrid RNA-DNA guide technology, which is intended to support precise and efficient genome editing.